News Breaks |
|
|
| January 4, 2013 |
| 18:23 EDT |  | PFE, ENDP | Pfizer, Endo Pharmaceuticals to pay $18.17M each to Texas in Medicaid case
Texas Attorney General Greg Abbott announced that two civil Medicaid fraud settlements secured by the Attorney General’s Office will yield more than $36M for the state, and the settlement agreements announced resolve the state’s Medicaid fraud claims against Pfizer (PFE) and Endo Pharmaceuticals (ENDP). Under the agreements, the state will recover $18.17M each from Pfizer and Endo Pharmaceuticals. Reference Link |
|
|
News For PFE;ENDP From The Last 14 Days Check below for free stories on PFE;ENDP the last two weeks. |
|
|
| June 10, 2013 |
| 07:20 EDT |  | PFE | Biomed to host a conference
 Subscribe for More Information |
|
| June 6, 2013 |
| 10:01 EDT |  | ENDP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 10:01 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:53 EDT | | ENDP | Endo Health upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 07:22 EDT |  | ENDP | Endo Health restructuring slightly ahead of schedule, says Jefferies
Subscribe for More Information |
|
| 06:34 EDT | | ENDP | Endo Health downgraded to Sell from Hold at Cantor
Subscribe for More Information |
|
| June 5, 2013 |
| 17:45 EDT | | ENDP | Endo terminates sales and promotional pact with Ventiv
Subscribe for More Information |
|
| 16:30 EDT |  | ENDP | Endo Health revises FY13 adjusted EPS view to $4.10-$4.40, consensus $4.27
Revises FY13 revenue guidance to $2.65B-$2.8B, consensus $2.8B. The company's 2013 guidance is based on certain assumptions including adjusted gross margin of between 64%-66%; adjusted effective tax rate of between 27.5%-28.5%; adjusted operating expenses to be reduced by approximately $150M when compared with FY12; the company continues to expect a single generic competitor for Lidoderm in September. |
|
| 16:23 EDT | | ENDP | Endo Health to explore strategic alternatives for HealthTronics business
In keeping with its more disciplined capital allocation framework, the company is evaluating strategic alternatives for its HealthTronics business, which provides urological services, products and support systems to various healthcare providers in the U.S. Endo also announced plans to explore alternatives for its branded pharmaceutical early stage discovery platform, which is made up of several drug discovery candidates in multiple therapeutic areas. The company will continue to evaluate the performance of its remaining businesses so that their respective cash flows and returns are consistent with Endo's investment criteria. |
|
| 16:23 EDT | | ENDP | Endo Health, announces strategic alternatives, to reduce workforce by 15%
Subscribe for More Information |
| |
|
|
|
|
